Similar articles

• Does interferon therapy prevent hepatocellular carcinoma in patients with chronic hepatitis C?

  Kowdley KV. Kowdley KV. Gastroenterology. 1999 Sep;117(3):738-9. doi: 10.1016/s0016-5085(99)70471-3. Gastroenterology. 1999. PMID: 10464154 No abstract available.
• Interferon therapy does not prevent hepatocellular carcinoma in HCV compensated cirrhosis.

  Testino G, Ansaldi F, Andorno E, Ravetti GL, Ferro C, De Iaco F, Icardi G, Valente U. Testino G, et al. Hepatogastroenterology. 2002 Nov-Dec;49(48):1636-8. Hepatogastroenterology. 2002. PMID: 12397752
• Incomplete response of interferon treatment has an important role for the prevention of hepatocellular carcinoma.

  Hayashi N. Hayashi N. J Gastroenterol. 1999 Oct;34(5):655-6. doi: 10.1007/s005350050392. J Gastroenterol. 1999. PMID: 10535501 No abstract available.
• Secondary prevention of recurrence by interferon therapy after ablation therapy for hepatocellular carcinoma in chronic hepatitis C patients.

  Ishikawa T. Ishikawa T. World J Gastroenterol. 2008 Oct 28;14(40):6140-4. doi: 10.3748/wjg.14.6140. World J Gastroenterol. 2008. PMID: 18985803 Free PMC article. Review.
• [Effects of IFN therapy on incidence of hepatocellular carcinoma in HCV positive cirrhosis].

  Nishiguchi S, Kubo S, Shiomi S. Nishiguchi S, et al. Nihon Rinsho. 2004 Jul;62 Suppl 7(Pt 1):600-4. Nihon Rinsho. 2004. PMID: 15359868 Review. Japanese. No abstract available.